targeted therapy – Medxy AI

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

By MedXY 09/09/2025

Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against approved doublet therapies.

Clinical Updates Wellness & Lifestyle

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

By MedXY 09/09/2025

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and treatment duration implications.

Clinical Updates Wellness & Lifestyle

Pemigatinib: A Breakthrough Targeted Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements

By MedXY 08/28/2025

Pemigatinib demonstrates high efficacy and manageable toxicity in treating MLN-FGFR1, especially in chronic-phase patients, addressing a critical unmet need in this aggressive neoplasm.

Clinical Updates Wellness & Lifestyle

Harnessing Exosomes in Neurodegenerative Diseases: Therapeutic Promise and Modification Techniques

By MedXY 08/20/2025

Exosomes, nanoscale vesicles capable of crossing the blood–brain barrier, hold significant potential as targeted therapeutic agents and diagnostic markers in neurodegenerative diseases. Advances in genetic, chemical, and nanomaterial modifications enhance their targeting, representing a promising frontier for treatment.

Clinical Updates Wellness & Lifestyle

A Century of Change: How Human Innovation Transformed Lung Cancer Treatment

By MedXY 08/03/2025

Lung cancer therapy has evolved from rudimentary surgery and misdiagnosis to a precision medicine era, markedly improving outcomes through targeted therapies and immunotherapy.

Clinical Updates Wellness & Lifestyle

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma

By MedXY 08/03/2025

A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV600E/K mutations.

Clinical Updates Wellness & Lifestyle

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

By MedXY 08/01/2025

Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.

Clinical Updates Wellness & Lifestyle

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

By MedXY 08/01/2025

Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.

Clinical Updates Wellness & Lifestyle

EMA Recommends Voranigo for IDH-Mutant Grade 2 Glioma: A New Era in Targeted Brain Tumor Therapy

By MedXY 07/30/2025

The EMA’s CHMP recommends Voranigo, a dual IDH1/2 inhibitor, for grade 2 IDH-mutant gliomas, based on phase 3 INDIGO trial results demonstrating significant improvement in progression-free survival and delayed need for further therapy.